Representation of women in clinical trials supporting FDA ‐approval of contemporary cancer therapies
International Journal of Cancer · 2024
DOI: 10.1002/ijc.35110 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Sujay Kalathoor und 26 weiteren Autor:innen. Beteiligte Einrichtung: Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Neoplasms, Drug Approval, Antineoplastic Agents, United States Food and Drug Administration. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health (NIH), NCATS NIH HHS.
Abstract (Originalsprache)
Contemporary anticancer therapies frequently have different efficacy and side effects in men and women. Yet, whether women are well‐represented in pivotal trials supporting contemporary anticancer drugs is unknown. Leveraging the Drugs@FDA database, clinicaltrials.gov , MEDLINE, and publicly available FDA‐drug‐reviews, we identified all pivotal (phase II and III) non‐sex specific trials supporting FDA‐approval of anticancer drugs (1998–2018). Observed‐enrollment‐rates were compared to expected‐population‐rates derived from concurrent US‐National‐Cancer‐Institute's Surveillance‐Epidemiology‐and‐End‐Results (SEER) reported rates and US‐Census databases. Primary outcome was the proportional representation of women across trials, evaluated by a participation‐to‐prevalence ratio (PPR), according to cancer type. Secondary outcome was the report of any sex‐specific analysis of efficacy and/or safety, irrespective of treatment‐arm. Overall, there were 148 trials, enrolling 60,216 participants (60.5 ± 4.0 years, 40.7% female, 79.1% biologic, targeted, or immune‐based therapies) evaluating 99 drugs. Sex was reported in 146 (98.6%) trials, wherein 40.7% (24,538) were women, compared to 59.3% (35,678) men ( p < .01). Altogether, women were under‐represented in 66.9% trials compared to the proportional incidence of cancers by respective disease type; weight‐average PPR of 0.91 (relative difference: ‐9.1%, p < .01). Women were most under‐represented in gastric (PPR = 0.63), liver (PPR = 0.71), and lung (PPR = .81) cancer trials. Sex‐based safety data was reported in 4.0% trials. There was no association between adequate female enrollment and drug efficacy (HR: 0.616 vs. 0.613, p = .96). Over time, there was no difference in the percentage of women recruited into clinical trials. Among pivotal clinical trials supporting contemporary FDA‐approved cancer drugs, women were frequently under‐represented and sex‐specific‐efficacy and safety‐outcomes were commonly not reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, Ohio, USA.
- Department of Medicine, Greater Baltimore Medical Center, Baltimore, Maryland, USA.
- Division of Oncology, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, Ohio, USA.
- Division of Cardiology, Indiana University, Indianapolis, Indiana, USA.
- Division of Cardiology, University of Virginia, Charlottesville, Virginia, USA.
- Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Sanam Ghazi
Förderung
- NHLBI NIH HHS
- National Institutes of Health (NIH)
- NCATS NIH HHS
- NCI NIH HHS
Zitieren
APA
Kalathoor, S., Ghazi, S., Otieno, B., Babcook, M. A., Chen, S., Nidhi, N., Bae, J., Pierre-Charles, J., Breathett, K., Mazimba, S., Johnson, A., Brewer, L., Mohammed, S., Carter, R. R., Bonsu, J. M., Ferdousi, M., Kola-Kehinde, O., McLaughlin, E., Brammer, J., …, & Addison, D. (2024). Representation of women in clinical trials supporting FDA ‐approval of contemporary cancer therapies. International Journal of Cancer. https://doi.org/10.1002/ijc.35110
Vancouver
Kalathoor S, Ghazi S, Otieno B, Babcook MA, Chen S, Nidhi N, et al. Representation of women in clinical trials supporting FDA ‐approval of contemporary cancer therapies. International Journal of Cancer. 2024. doi:10.1002/ijc.35110
BibTeX
@article{Kalathoor2024,
author = {Kalathoor, Sujay and Ghazi, Sanam and Otieno, Beryl and Babcook, Melissa A and Chen, Sunnia and Nidhi, Neha and Bae, Junu and Pierre-Charles, Jovan and Breathett, Khadijah and Mazimba, Sula and Johnson, Amber and Brewer, LaPrincess and Mohammed, Selma and Carter, Rebecca R and Bonsu, Janice M and Ferdousi, Mussammat and Kola-Kehinde, Onaopepo and McLaughlin, Eric and Brammer, Jonathan and Ruz, Patrick and Khan, Sarah and Odei, Bismarck and Mitchell, Darrion and Wei, Lai and Patel, Prem and Paskett, Electra D and Addison, Daniel},
title = {Representation of women in clinical trials supporting FDA ‐approval of contemporary cancer therapies},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.35110}
}
EUVIMED